Neuromodulation Devices Market Scope and Key Players Analysis by 2030
Neuromodulation Devices Market Report Scope
| Report Attribute | Details |
|---|---|
| Market size in 2022 | US$ 5.73 Billion |
| Market Size by 2030 | US$ 11.61 Billion |
| Global CAGR (2022 - 2030) | 9.2% |
| Historical Data | 2020-2022 |
| Forecast period | 2022-2030 |
| Segments Covered |
By Type
|
| Regions and Countries Covered | North America
|
| Market leaders and key company profiles |
Competitive Landscape and Key Companies:
The neuromodulation devices market report is focused on prominent players in the market such as Abbott (St. Jude Medical, Inc), LivaNova PLC, Boston Scientific Corporation, Aleva Neurotherapeutics SA, Bioventus, EnteroMedics Inc, Nevro Corporation, NeuroPace Inc, Synapse Biomedical Inc, and Neurosigma Inc. The neuromodulation devices market forecast can help stakeholders plan their growth strategies. These companies focus on new technologies, upgrading existing products, and market expansions to meet the growing consumer demand across the world. As per company press releases, below are a few recent key developments:
- In August 2023, Medtronic plc received CE Mark approval for its Inceptiv closed-loop rechargeable spinal cord stimulator (SCS). It is the first Medtronic SCS device to offer a closed-loop feature that senses each person's unique biological signals and adjusts stimulation moment to moment, as needed, to keep therapy in harmony with the motions of daily life.
- In August 2023, Abbott received approval from the US Food and Drug Administration (FDA) for its new Proclaim Plus spinal cord stimulation (SCS) system featuring FlexBurst360 therapy. The next generation of Abbott's proprietary BurstDR stimulation, FlexBurst360 therapy offers pain coverage across six areas of the trunk and/or limbs. It facilitates programming that can be adjusted as per a person’s therapeutic needs.
Get Free Sample For